PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). CONCLUSIONS: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
PURPOSE:Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). CONCLUSIONS: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
Authors: Sophia W M Bruggeman; Merel E Valk-Lingbeek; Petra P M van der Stoop; Jacqueline J L Jacobs; Karin Kieboom; Ellen Tanger; Danielle Hulsman; Carly Leung; Yvan Arsenijevic; Silvia Marino; Maarten van Lohuizen Journal: Genes Dev Date: 2005-06-15 Impact factor: 11.361
Authors: R G Sewalt; J van der Vlag; M J Gunster; K M Hamer; J L den Blaauwen; D P Satijn; T Hendrix; R van Driel; A P Otte Journal: Mol Cell Biol Date: 1998-06 Impact factor: 4.272
Authors: R H J Breuer; P J F Snijders; G T Sutedja; R G A B Sewalt; A P Otte; P E Postmus; C J L M Meijer; F M Raaphorst; E F Smit Journal: Lung Cancer Date: 2005-06 Impact factor: 5.705
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: S Vonlanthen; J Heighway; H J Altermatt; M Gugger; A Kappeler; M M Borner; M van Lohuizen; D C Betticher Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640
Authors: V Häyry; L K Mäkinen; T Atula; H Sariola; A Mäkitie; I Leivo; H Keski-Säntti; J Lundin; C Haglund; J Hagström Journal: Br J Cancer Date: 2010-02-09 Impact factor: 7.640
Authors: Jennifer Shepard Dovey; Sima J Zacharek; Carla F Kim; Jacqueline A Lees Journal: Proc Natl Acad Sci U S A Date: 2008-08-12 Impact factor: 11.205